# 510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION DECISION SUMMARY

A. 510(k) Number: k061970   
B. Purpose for Submission: Modification to the manufacturerâ€™s existing device including changes to a strictly monobiotinylated monoclonal antibody (the antibody itself remains unchanged), deletion of an application for the Elecsys 1010 analyzer and modifications to specifications for linearity, intra-assay and inter-assay precision.   
C. Measurand: Quantitative determination of IgE in human serum and plasma   
D. Type of Test: Immunoassay   
E. Applicant: Roche Diagnostics.   
F. Proprietary and Established Names: Elecsys IgE II immunoassay

# G. Regulatory Information:

2. Classification: Class II

3. Product code: JHR, Radioimmunoassay, Immunoglobulins (D, E)

4. Panel: Immunology (82)

# H. Intended Use:

1. Intended use(s): Immunoassay for the in vitro quantitative determination of immunoglobulin E in human serum and plasma. Determination of total IgE is useful as an aid in the diagnosis of allergic diseases.   
2. Indication(s) for use: Same as Intended Use   
3. Special conditions for use statement(s): For Prescription use only   
4. Special instrument requirements:

# I. Device Description:

The Elecsys IgE II immunoassay is a two step sandwich immunoassay with streptavidin microparticles and electrochemiluminescence detection. Results are determined using a calibration curve that is generated specifically on each instrument by a 2 point calibration and a master curve provided with the reagent bar code.

J. Substantial Equivalence Information:

1. Predicate device name(s):

Elecsys IgE immunoassay

2. Predicate 510(k) number(s): (K984326, K961481/A003)

3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=1>Topic</td><td rowspan=1 colspan=1>Elecsys IgE (K984326,K961481/A003)</td><td rowspan=1 colspan=1>Elecsys IgE II (Modified Device)</td></tr><tr><td rowspan=1 colspan=1>Intended use</td><td rowspan=1 colspan=1>Immunoassay for the in vitroquantitative determination ofimmunoglobulin E in human serumand plasma. Determination of totalIgE is useful as an aid in the diagnosisof allergic diseases.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Analyzers</td><td rowspan=1 colspan=1>Roche Elecsys 1010/2010 andMODULAR ANALYTICS E170(Elecsys module) immunoassayanalyzers.</td><td rowspan=1 colspan=1>Roche Elecsys 2010 and MODULARANALYTICS E170 (Elecsys module)immunoassay analyzers.</td></tr><tr><td rowspan=1 colspan=1>Traceability</td><td rowspan=1 colspan=1>Assay standardized against the 2nd IRPWHO Reference Standard 75/502</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Assay Protocol</td><td rowspan=1 colspan=1>Sandwich</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=1>Serum and plasma</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Calibrator,CalibrationVerification &amp;Controls</td><td rowspan=1 colspan=1>IgE CalSetIgE CalCheckPreciControl Universal</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>MeasuringRange</td><td rowspan=1 colspan=1>0.100 - 2500 IU/ml</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>AnalyticalSensitivity</td><td rowspan=1 colspan=1>0.10 IU/ml</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>FunctionalSensitivity</td><td rowspan=1 colspan=1>0.50 IU/ml</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Composition</td><td rowspan=1 colspan=1>R1: 2.4 mg/L AB-Bi, buffer,preservativeR2: 4.8 mg/L AB-Ru, buffer,preservativeM: 0.72 mg/ml streptavidin-coatedmicroparticles, preservative</td><td rowspan=1 colspan=1>R1: 2.5 mg/L (mono-Bi)AB-Bi,buffer, preservativeR2: 5.5 mg/L AB-Ru, buffer,preservativeM: 0.72 mg/ml streptavidin-coatedmicroparticles, preservative</td></tr><tr><td rowspan=1 colspan=1>DilutionRecommendation</td><td rowspan=1 colspan=1>Concentration of diluted samples mustbe &gt; 60 IU/mL</td><td rowspan=1 colspan=1>Concentration of diluted samples mustbe &gt; 125 IU/mL</td></tr></table>

# K. Standard/Guidance Document Referenced (if applicable):

L. Test Principle: Same

M. Performance Characteristics (if/when applicable):

1. Analytical performance: a. Precision/Reproducibility:

# Special 510(k): Device Modification - Elecsys IgE II Immunoassay, continued

<table><tr><td>Topic</td><td colspan="2">Elecsys IgE (K984326, K961481/A003)</td><td colspan="2">Elecsys IgE II (Modified Device)</td></tr><tr><td>Interferences</td><td colspan="2">No affect up to, bilirubin &lt; 37 mg/dl hemoglobin &lt; 1.1 g/dl triglycerides&lt; 2200 mg/dl</td><td colspan="2">No affect up to, Bilirubin - Same hemoglobin &lt; 0.1 g/dl</td></tr><tr><td>Precision</td><td colspan="2">biotin &lt; 100 ng/ml Elecsys 1010 / 2010: Intra-assay HS1 3.6% CV@ 5.18 IU/mL HS2 3.2% CV @</td><td colspan="2">biotin- Same Elecsys 2010: Intra-assay: HS1 4.1% CV@ 32.7 IU/mL</td></tr></table>

b. Linearity/assay reportable range: Not applicable   
c. Traceability, Stability, Expected values (controls, calibrators, or methods):   
d. Detection limit: Same   
e. Analytical specificity: Same   
f. Assay cut-off: Not applicable.

2. Comparison studies:

a. Method comparison with predicate device:

b. Matrix comparison: Not applicable

. Clinical studies: a. Clinical Sensitivity: No change. b. Clinical specificity: No change. c. Other clinical supportive data (when a. and b. are not applicable): Not applicable.

4. Clinical cut-off: Not applicable.

N. Software:

O. Proposed Labeling:

# P. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.